摘要
非瓣膜性心房颤动（nonvalvul aratrial fibrillation，NVAF）是最常见的心律失常类型，同时也是缺血性卒中的独立危险因素。华法林能有效降低NVAF患者的缺血性卒中风险，但会大幅增高严重出血风险。目前，多数临床指南均推荐使用CHADS2评分对NVAF患者的卒中风险进行分层以指导抗栓治疗。虽然使用简单而且方便，但CHADS2评分因存在许多局限性而受到争议，特别是未纳入一些常见的卒中危险因素。相比之下，CHA2DS2-VASc评分纳入了更多卒中危险因素，能更好地识别真正的低危患者，在CHADS2评舯～1分的AF患者中，CHA2DS2-VASc评分能提供卒中风险的重要信息，从而帮助抗凝治疗的决策。
Nonvalvular atrial fibrillation （NVAF） is the most common type of arrhythmia and an independent risk factor for ischemic stroke. Warfarin effectively decreases the risk factors for ischemic stroke in patients with NVAF, but substantially increases the risk for severe bleeding, Currently, most clinical guidelines recommend using the CHADS2 score for stroke risk stratification in NVAF patients to guide antithrombotic treatment. Although its application is simple and convenient, the CHADS2 score has been debated because of many limitations; especially some common stroke risk factors were not included. By comparison, the CHA^DS2-VASc scores have included more risk factors for stroke. It can better identify the truly low-risk patients. Among the AF patients with CHADS2 score of 0 to 1, CHA：DS2-VASc scores may provide the important information for stroke risk, and thus help the decision-making of the anticoagulant therapy.
出处
《国际脑血管病杂志》
北大核心
2012年第7期519-523,共5页
International Journal of Cerebrovascular Diseases
关键词
心房颤动
卒中
危险性评估
危险因素
抗凝药
Atrial Fibrillation
Stroke
Risk Assessment
Risk Factors
Anticoagulants
